- CA$31.79m
- CA$30.13m
- CA$37.42m
- 99
- 83
- 43
- 89
Annual income statement for Biorem, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 24.4 | 24.5 | 28.9 | 25.2 | 37.4 |
| Cost of Revenue | |||||
| Gross Profit | 7.02 | 6.24 | 8.76 | 7.02 | 10.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 21.7 | 22.4 | 26.2 | 22.1 | 33.1 |
| Operating Profit | 2.72 | 2.07 | 2.64 | 3.06 | 4.34 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 2.68 | 2.03 | 2.38 | 2.79 | 4.15 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.09 | 1.3 | 1.61 | 2.18 | 3.04 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2.09 | 1.3 | 1.61 | 2.18 | 3.04 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.09 | 1.3 | 1.61 | 2.18 | 3.04 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.047 | 0.084 | 0.104 | 0.139 | 0.193 |